- Research article
- Open Access
qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL
© Fassunke et al; licensee BioMed Central Ltd. 2010
- Received: 30 July 2010
- Accepted: 20 December 2010
- Published: 20 December 2010
Gastrointestinal stromal tumors (GIST) represent the most common mesenchymal tumors of the gastrointestinal tract. About 85% carry an activating mutation in the KIT or PDGFRA gene. Approximately 10% of GIST are so-called wild type GIST (wt-GIST) without mutations in the hot spots. In the present study we evaluated appropriate reference genes for the expression analysis of formalin-fixed, paraffin-embedded and fresh frozen samples from gastrointestinal stromal tumors. We evaluated the gene expression of KIT as well as of the alternative receptor tyrosine kinase genes FLT3, CSF1-R, PDGFRB, AXL and MET by qPCR. wt-GIST were compared to samples with mutations in KIT exon 9 and 11 and PDGFRA exon 18 in order to evaluate whether overexpression of these alternative RTK might contribute to the pathogenesis of wt-GIST.
Gene expression variability of the pooled cDNA samples is much lower than the single reverse transcription cDNA synthesis. By combining the lowest variability values of fixed and fresh tissue, the genes POLR2A, PPIA, RPLPO and TFRC were chosen for further analysis of the GIST samples. Overexpression of KIT compared to the corresponding normal tissue was detected in each GIST subgroup except in GIST with PDGFRA exon 18 mutation. Comparing our sample groups, no significant differences in the gene expression levels of FLT3, CSF1R and AXL were determined. An exception was the sample group with KIT exon 9 mutation. A significantly reduced expression of CSF1R, FLT3 and PDGFRB compared to the normal tissue was detected. GIST with mutations in KIT exon 9 and 11 and in PDGFRA exon 18 showed a significant PDGFRB downregulation.
As the variability of expression levels for the reference genes is very high comparing fresh frozen and formalin-fixed tissue there is a strong need for validation in each tissue type. None of the alternative receptor tyrosine kinases analyzed is associated with the pathogenesis of wild-type or mutated GIST. It remains to be clarified whether an autocrine or paracrine mechanism by overexpression of receptor tyrosine kinase ligands is responsible for the tumorigenesis of wt-GIST.
- Reference Gene
- Gastrointestinal Stromal Tumor
- Malignant Peripheral Nerve Sheath Tumor
- FFPE Tissue
- Candidate Reference Gene
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract and are characterized by the expression of the KIT receptor (stem cell factor receptor, CD117) and to a lesser extent of PDGFRA (platelet derived growth factor receptor alpha), representing two closely related receptor tyrosine kinases (RTK) [1, 2]. The majority of GIST shows oncogenic mutations either in KIT or PDGFRA[3, 4]. Mainly, mutations in exon 9 or 11 of the KIT gene or in exon 18 of PDGFRA lead to ligand independent, constitutive activation of the kinase function . About 60% of all GIST carry an exon 11 mutation of KIT which encodes the juxtamembrane domain of the receptor possessing an autoinhibitory function [6, 7]. Less common mutations in PDGFRA (~ 10%) are detected in GIST that often display gastric location and epithelioid morphology .
In a minority of cases (10-15%) no mutations in the known KIT or PDGFRA hot spots are detected although these tumors express the KIT protein. This subgroup is called wild type GIST (wt-GIST) and comprises tumors in pediatric patients, in patients affected by the Carney triad, neurofibromatosis type 1 (NF1) associated GIST and a subset of sporadic adult GIST [8–11]. The pathogenetic mechanisms underlying wt-GIST are poorly understood and there is limited benefit of imatinib therapy in these patients . Therefore the identification of additional genetic factors contributing to the pathogenesis of GIST may help to find new concepts of individualized therapy.
Recently, the BRAF mutation p.V600E was found in 4-13% of wt-GIST [13–15]. For another subgroup of wt-GIST including pediatric tumors, a strong IGF1R expression combined partly with gene amplification was described [16–18]. Two other alternative RTK probably involved in the pathogenesis of GIST are AXL and MET. Both kinases have been shown to be upregulated in GIST resistant to treatment . AXL is a member of the Ufo/AXL subfamily and activates the same signaling pathway as KIT. The tyrosine kinase domain of MET is mutated in sporadic papillary renal carcinomas. Some mutations in the MET gene are located in codons homologous to those in KIT and it is suggested that these missense mutations lead to constitutive activation of the MET protein . To develop additional therapy approaches it would be of interest to know whether this RTK also plays a role in wt-GIST.
Besides KIT and PDGFRA, CSF1R (colony stimulating factor 1 receptor), FLT3 (fms like tyrosine kinase 3) and PDGFRB (platelet derived growth factor receptor β) belong to the same family of type III RTK. These five tyrosine kinases show a homologous structure and a comparable function in activation, proliferation and suppressing apoptosis [21–23].
Aberrant expression and mutations in either CSF1R, FLT3 and PDGFRB or their ligands have been described in several malignant diseases. Overexpression of CSF1R is found in epithelial tumors such as breast and ovarian cancer . The translocation t(1;2) of its ligand CSF1 leads to the development of the tenosynovial giant cell tumor .
Aberrantly expressed FLT3 is observed at high levels in a spectrum of hematologic malignancies . Additionally, in AML an internal tandem duplication in the transmembrane domain of FLT3 was identified which leads to constitutive activation of its kinase domain. It seems that this mutation is not present or very rare in GIST .
To analyse expression profiles of certain tumors for research and diagnostic purposes, qPCR (quantitative PCR) is frequently applied because of its reproducibility and high sensitivity [30, 31]. This method is based on the normalization of the target gene expression on stably expressed internal reference genes. A major challenge is the application of suitable reference genes which have to be tested and verified under defined experimental conditions [32, 33]. Ideal reference genes have to be non-regulated, stable and not affected by biological or experimental conditions. The target gene is amplified together with the reference gene in order to minimize experimental variability concerning reverse transcription enzymatic efficiencies, PCR efficiency, amount of starting material and differences between human tissues. The reference gene and the target gene should have very robust and stable expression profiles to ensure accurate normalization and interpretation of results. The most stable expressed gene from a set of genes can be identified by geNorm , a software program which additionally provides the number of genes required to calculate a robust normalization factor based on the geometric mean of these genes.
Typical reference genes regulate basic and ubiquitous cellular functions and are responsible for the cellular maintenance, e.g. GAPDH or ß-actin. However, these commonly used reference genes vary considerably in different tissue types or under different experimental conditions [35, 36]. There is no standard reference gene for all kinds of tissue types. To our best knowledge only few studies investigated the alteration of stability of reference genes in different mesenchymal tumour entities.
In the present study we attempted to identify suitable reference genes in gastrointestinal stromal tumors by using a set of sixteen reference genes which are currently applied in qPCR procedures. Furthermore we evaluated the gene expression of KIT as well as the alternative RTK FLT3, CSF1-R, PDGFRB, AXL and MET in mutated and non-mutated gastrointestinal stromal tumors by qPCR using the identified reference genes. The study was focussed on wt-GIST compared to samples with mutations in KIT exon 9 and 11 and PDGFRA exon 18 in order to evaluate whether overexpression of these alternative RTK might contribute to the pathogenesis of wt-GIST.
A total of 107 samples were included into this study. All specimens were obtained in the years 2005 and 2006 under approved ethical protocols and with informed consent from each patient. All samples were fixed in neutral-buffered formalin prior to paraffin embedding. 20 samples from normal tissue (i.e., muscularis propria of stomach and gut) as control group and 87 GIST representing different mutational subgroups were evalutated. 20 samples of wt-GIST, 7 samples of wt-GIST associated with neurofibromatosis type 1, 20 samples with exon 9 mutation in KIT, 20 samples with exon 11 mutation in KIT and 20 samples with exon 18 mutation in PDGFRA). Sequence analysis of KIT (exons 8, 9, 11, 13, 14, 15 and 17) and PDGFRA (exons 12, 14 and 18) was carried out as described earlier [1, 37, 38]. Additionally, in all samples the wild type status of the BRAF gene was ascertained. All GIST samples were stained immunohistochemically for CD117. Four normal tissues from the gastrointestinal region were available as fresh frozen and formalin-fixed, paraffin-embedded samples.
RNA extraction and cDNA synthesis
Prior to RNA extraction, paraffin-embedded tissues were cut into 10 μm sections and mounted on glass-slides. Six slides of each specimen were used for RNA extraction. The sections were deparaffinized by extracting twice in xylene for 10 min at room temperature. Rehydration was done in 100% ethanol, 90% ethanol, 80% ethanol and 70% ethanol made with DEPC-water for 10 min each. Tumor areas previously marked on a H&E slide were scraped from the sections with a sterile scalpel. Sections were transferred into a sterile 1.5 ml tube. Extraction and purification of RNA was done using the RNeasy FFPE KIT (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. After tumor localization by H&E staining fresh frozen material was rasped into 10 μm thick pieces and RNA purification was carried out using the RNeasy Kit (Qiagen, Hilden, Germany). Both RNeasy Kits contain a step of DNase treatment. Finally RNA from fresh and from fixed tissue was eluted in water. The quantification was done spectrophotometrically (NanoDrop, PeqLab Technology, Erlangen, Germany). 500 ng of RNA from each sample was reverse-transcribed using a random-hexamer primer and Avian Myoblastosis Virus reverse transcriptase (AMV-RT) according to the manufacturer's protocol (Qiagen). cDNA from those four fresh frozen and corresponding formalin-fixed, paraffin-embedded (FFPE) control samples was generated in only one reverse transcription and loaded on the reference low density arrays (see below). Further cDNA samples were generated from the four FFPE control tissues, pooled within one patient and loaded onto a second independent reference low density array.
Identification of reference genes
Selected candidate reference genes for gene expression analysis.
18S ribosomal RNA
major histocompatibility complex
metabolic salvage of purines
intracellular protein transport
phosphoglycerate kinase 1
DNA-dependent RNA polymerase II
peptidyl-prolyl isomerase A
ribosomal phosphoprotein, large, P0
cellular iron uptake
tyrosine 3-/tryptophan 5-Monooxygenase-activation protein, zeta isoform
Analyses of gene expression by qPCR
Gene-specific qPCR assays.
colony stimulating factor 1 receptor
tyrosine protein kinase receptor
fms-related tyrosine kinase 3
tyrosine protein kinase receptor
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
tyrosine protein kinase receptor
platelet-derived growth factor receptor, beta
tyrosine protein kinase receptor
hepatocyte growth factor receptor
AXL receptor tyrosine kinase
tyrosine protein kinase receptor
The geNorm applet for Microsoft Excel was used to determine the most stable genes among the sixteen candidate reference genes. Raw Cq values were converted into relative quantities for analysis with geNorm, where the highest relative quantity for each gene is set to 1. The program selects from a panel of candidate reference genes the two most stable genes or a combination of multiple stable genes for normalization. The gene expression stability (M) value is based on the combined estimate of intra- and intergroup expression variations of the genes studied and takes the PCR efficiency into account. The limited M-value is 1.5. The most stable genes are stepwise selected from the investigated gene panel to estimate how many reference genes should be used. The normalization factors define the optimal number of reference genes required for a precised normalization design. The analysis of the expression data of tumor samples compared to control samples was performed with the REST software (Relative Expression Software Tool) . The software normalizes the measured Cq-values of the target genes with those of the reference genes and compares the expression data of tumor and control samples by considering the PCR efficiency and the mean crossing point deviation.
RNA quality of the samples was inspected on a 1% agarose gel. The concentration and purity of the RNA was characterized by the mean A260/280 ratio and was on average 1.99 for fresh frozen as well as for formalin fixed, paraffin-embedded samples and reflected pure and protein-free RNA.
Expression variability of cDNA synthesis
Identification of suitable reference genes for normalization
Expression profiles of KIT, FLT3, CSF1-R, PDGFRB, AXL and MET
Expression analysis of target genes.
The other target genes, FLT3, CSF1R, PDGFRB, AXL and MET showed lower expression levels in the tumor tissue compared to normal tissue except AXL in NF1 associated GIST. MET was even significantly reduced in wt-GIST, KIT exon 9, 11 and PDGFRA exon 18 mutated GIST. No changes in expression levels were detected comparing normal tissue and wt-GIST with KIT exon 11 mutated GIST, indicating that both groups possess similar expression levels for the analyzed receptors. None of the groups showed significant expression alterations for CSF1R and FLT3. An exception is the group of KIT exon 9 mutated GIST. A lower expression of CSF1R, FLT3, PDGFRB and MET compared to normal tissue was identified in contrast to KIT, which showed a significant overexpression. In summary, overexpression of KIT was detected in each GIST subgroup compared to the corresponding normal tissue by using the preassigned reference gene POLR2A (table 3). GIST with a mutation in exon 18 of PDGFRA did not show a significant upregulation of KIT compared to normal tissue. GIST with a mutation in KIT exon 9, 11 and in the PDGFRA exon 18 showed significant PDGFRB downregulation.
Most gastrointestinal stromal tumors exhibit mutations in exon 11 of the KIT gene. This exon encodes for the juxtamembrane domain of the receptor which possesses an autoinhibitory function. In wt-GIST, activating mutations are found neither in the KIT nor in the PDGFRA gene. Clinical treatment with the tyrosine kinase inhibitor imatinib targets the ATP binding site in the kinase domain of the KIT receptor. In wt-GIST, response to treatment is often poor  although most of them overexpress the KIT protein. A screen for activating mutations in the juxtamembrane domain of the alternative receptor tyrosine kinases CSF1R, FLT3, PDGFRB in 30 wt-GIST samples yielded only wild type sequences (data not shown) in agreement with previously published results . Therefore we investigated in this study whether the expression of alternative receptor tyrosine kinases may contribute to the pathogenesis of wt-GIST and thus may help to identify wt-GIST subgroups with different response to imatinib and elucidate novel therapeutic targets.
The pathogenesis of several malignant tumors is associated with overexpression of CSF1R and PDGFRB [24, 28]. Imatinib inhibits cell invasion in malignant peripheral nerve sheath tumors by blocking PDGFRB  and it has been found to have antitumor activity in patients with chordoma . In our study, the gene-expression level of CSF1R, FLT3 and PDGFRB was determined in a cohort of 87 GIST samples. Furthermore, we assessed the expression of AXL and MET, two receptor tyrosine kinases which were found to be alternatively activated in therapy resistant GIST .
Gene expression analysis by qPCR requires suitable reference genes. The expression of reference genes like GAPDH or BETA-ACTIN is regulated differentially depending on the tissue type. Therefore they are not suited as univocal reference genes [35, 43]. The determination of reference genes with stable expression in the experimental system used is essential to ensure accurate normalization and interpretation of results.
Whereas fresh tissue is frequently not available for genetic analysis, FFPE material is the standard. After formalin-fixation and paraffin-embedding of tissue, the isolated RNA is often heavily fragmented. In our study we used fresh as well as fixed material from the gastrointestinal tract to determine suitable reference genes and to analyze whether their expression levels are comparable. We then validated the reference genes by qPCR in our GIST cohort.
As reported also by others [44, 45] the variability of expression levels for the reference genes was very diverse comparing fresh frozen and formalin-fixed tissue. Therefore, we decided to validate separate reference genes for each tissue type.
The genes TRFC, POLR2A, PPIA and RPLPO were validated as appropriate reference genes for FFPE tissue. For fresh frozen tissue, PPIA and RPLPO were also found to be suitable. Additionally, UBC is suited as a reference gene in fresh frozen tissue. The variability of the reference genes for fresh frozen tissue was lower than for fixed tissue. To overcome the problem of high variability in FFPE tissue, we pooled two independent cDNA syntheses from one sample as recommended in the MIQE guidelines [30, 46]. The MIQE guidelines give considerations for a consistent application of the qPCR technology including experimental details, data analysis and reporting principles. Unequal efficiency of cDNA synthesis might be a reason for deviation. Additionally, we tried to select consistent patient material for our cohort by choosing paraffin blocks having the same age. It was shown by Bibikova , that Cq-values in qPCR experiments depend on the age and condition of the tissue blocks. Because the expression value depends also on amplicon length [30, 44], only primer sets generating amplicons of about 100 bp were chosen for qPCR. This corresponds to the fragment length of degraded RNA between 100 and 200 bp. The application of the MIQE guidelines results in a minimum variability for reference genes. In summary, considering the MIQE guidelines FFPE material can be used reliably for expression analysis in GIST, but the use of separate reference genes for FFPE tissue is indispensable.
Our qPCR analysis included GIST with wild type sequences in the hot-spot regions of KIT and PDGFRA (wt-GIST), KIT exon 9 and exon 11 mutated samples, PDGFRA exon 18 mutated samples, NF-1-associated wt-GIST and normal tissue controls. The wt-GIST and the samples with the two different KIT mutations showed a significantly increased expression of KIT in contrast to the normal tissue. The results correspond to the immunohistochemical stainings of our samples and were in agreement with published data . It was shown immunohistochemically that PDGFRA mutated GIST have only a slightly increased protein expression of KIT. Our data revealed the same trend on RNA level compared to the normal tissue. Additionally, we could show in all groups of mutated GIST a significantly reduced expression of PDGFRB compared to the normal tissue. This could be due to the concomitant increase of KIT expression. When comparing NF-1-associated GIST without KIT mutation with wt-GIST without NF-1 association the latter showed a lower expression of KIT. Thus, the results of the two wt-GIST groups give a heterogenous profile, which suggests that different genomic events may be responsible for the development of these tumors.
Comparing our sample groups with each other, no significant difference in the gene expression levels of FLT3, CSF1R and AXL were determined. An exception was seen in the sample group with KIT exon 9 mutation. Here, a significantly reduced expression of CSF1R, FLT3 and PDGFRB compared to the normal tissue was detected. The results lead us to the assumption that KIT exon 9 mutated GIST play a special role compared to GIST carrying other mutations. Interestingly, KIT exon 9 mutated GIST need a double daily dose of the tyrosine kinase inhibitor imatinib to be effectively treated . Furthermore, they develop preferentially in the small intestine but only rarely in the stomach where the majority of GIST are detected .
All qPCR data were calculated four times with TRFC, POLR2A, PPIA and RPLPO as reference genes using the REST software. Concordant results with the four reference genes are based on the extensive and complex preselection of our cohort and the preparation of cDNA synthesis according to the MIQE guidelines.
In summary, we conclude that none of the alternative receptor tyrosine kinases analyzed here are associated with the pathogenesis of wild type or mutated GIST. It remains to be clarified whether an increased expression of receptor tyrosine kinase ligands is responsible for tumorigenesis of wt-GIST as it is described for dermatofibrosarcoma protuberans (DFSP) and tenosynovial giant cell tumor (TGCT) [25, 50]. Further studies are needed to elucidate the role of ligand-driven pathogenesis in wt-GIST.
Acknowledgements and Funding
This study was supported by a grant of the BONFOR programme of the Bonn Medical centre to HUS.
- Pauls K, Merkelbach-Bruse S, Thal D, Buttner R, Wardelmann E: PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology. 2005, 46: 166-175. 10.1111/j.1365-2559.2005.02061.xView ArticlePubMedGoogle Scholar
- Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M: CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998, 11: 728-734.PubMedGoogle Scholar
- Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A: PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003, 299: 708-710. 10.1126/science.1079666View ArticlePubMedGoogle Scholar
- Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998, 279: 577-580. 10.1126/science.279.5350.577View ArticlePubMedGoogle Scholar
- Lasota J, Miettinen M: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008, 53: 245-266. 10.1111/j.1365-2559.2008.02977.xView ArticlePubMedGoogle Scholar
- Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001, 61: 8118-8121.PubMedGoogle Scholar
- Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, Heinicke T, Pietsch T, Buttner R, Merkelbach-Bruse S: Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer. 2003, 106: 887-895. 10.1002/ijc.11323View ArticlePubMedGoogle Scholar
- Lasota J, Miettinen M: KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol. 2006, 23: 91-102. 10.1053/j.semdp.2006.08.006View ArticlePubMedGoogle Scholar
- Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, Fletcher JA, Fletcher CD: KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004, 28: 889-894. 10.1097/00000478-200407000-00007View ArticlePubMedGoogle Scholar
- Miettinen M, Fetsch JF, Sobin LH, Lasota J: Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006, 30: 90-96. 10.1097/01.pas.0000176433.81079.bdView ArticlePubMedGoogle Scholar
- Miettinen M, Lasota J, Sobin LH: Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol. 2005, 29: 1373-1381. 10.1097/01.pas.0000172190.79552.8bView ArticlePubMedGoogle Scholar
- Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H: Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004, 40: 689-695. 10.1016/j.ejca.2003.11.025View ArticlePubMedGoogle Scholar
- Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, Bringuier PP, Scoazec JY, Coindre JM: BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010, 133: 141-148. 10.1309/AJCPPCKGA2QGBJ1RView ArticlePubMedGoogle Scholar
- Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes JM: Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Histopathology. 2009, 55: 53-62. 10.1111/j.1365-2559.2009.03323.xView ArticlePubMedGoogle Scholar
- Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP: V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol. 2009, 62: 613-616. 10.1136/jcp.2009.064550View ArticlePubMedGoogle Scholar
- Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA: Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer. 2010, 127: 2718-2722. 10.1002/ijc.25247View ArticlePubMedPubMed CentralGoogle Scholar
- Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, Santini D, Catena F, Manara MC, Nannini M: Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer. 2009, 125: 2991-2994. 10.1002/ijc.24595View ArticlePubMedGoogle Scholar
- Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK: Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA. 2008, 105: 8387-8392. 10.1073/pnas.0803383105View ArticlePubMedPubMed CentralGoogle Scholar
- Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H: A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007, 26: 3909-3919. 10.1038/sj.onc.1210173View ArticlePubMedGoogle Scholar
- Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997, 16: 68-73. 10.1038/ng0597-68View ArticlePubMedGoogle Scholar
- Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985, 230: 1132-1139. 10.1126/science.2999974View ArticlePubMedGoogle Scholar
- Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O: The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. J Biol Chem. 1998, 273: 14962-14967. 10.1074/jbc.273.24.14962View ArticlePubMedGoogle Scholar
- Yarden Y, Escobedo JA, Kuang WJ, Yang-Feng TL, Daniel TO, Tremble PM, Chen EY, Ando ME, Harkins RN, Francke U: Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature. 1986, 323: 226-232. 10.1038/323226a0View ArticlePubMedGoogle Scholar
- Kacinski BM: CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev. 1997, 46: 71-74. 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6View ArticlePubMedGoogle Scholar
- West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E: A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA. 2006, 103: 690-695. 10.1073/pnas.0507321103View ArticlePubMedPubMed CentralGoogle Scholar
- Drexler HG: Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia. 1996, 10: 588-599.PubMedGoogle Scholar
- Shiozawa E, Takimoto M, Makino R, Hirayama Y, Ota H: Flt3/Itd mutation is not associated with gastrointestinal stromal tumors (gists). J Gastroenterol Hepatol. 2005, 20: 1132-1134. 10.1111/j.1440-1746.2005.03834.xView ArticlePubMedGoogle Scholar
- Perrone F, Da Riva L, Orsenigo M, Losa M, Jocolle G, Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S: PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol. 2009, 11: 725-736. 10.1215/15228517-2009-003View ArticlePubMedPubMed CentralGoogle Scholar
- Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F: Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res. 2006, 12: 6920-6928. 10.1158/1078-0432.CCR-06-1584View ArticlePubMedGoogle Scholar
- Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009, 55: 611-622. 10.1373/clinchem.2008.112797View ArticlePubMedGoogle Scholar
- Fleige S, Pfaffl MW: RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med. 2006, 27: 126-139. 10.1016/j.mam.2005.12.003View ArticlePubMedGoogle Scholar
- Ohl F, Jung M, Radonic A, Sachs M, Loening SA, Jung K: Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. J Urol. 2006, 175: 1915-1920. 10.1016/S0022-5347(05)00919-5View ArticlePubMedGoogle Scholar
- Saviozzi S, Cordero F, Lo Iacono M, Novello S, Scagliotti GV, Calogero RA: Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer. BMC Cancer. 2006, 6: 200- 10.1186/1471-2407-6-200View ArticlePubMedGoogle Scholar
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3: RESEARCH0034- 10.1186/gb-2002-3-7-research0034View ArticlePubMedPubMed CentralGoogle Scholar
- Bustin SA, Benes V, Nolan T, Pfaffl MW: Quantitative real-time RT-PCR--a perspective. J Mol Endocrinol. 2005, 34: 597-601. 10.1677/jme.1.01755View ArticlePubMedGoogle Scholar
- Tricarico C, Pinzani P, Bianchi S, Paglierani M, Distante V, Pazzagli M, Bustin SA, Orlando C: Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies. Anal Biochem. 2002, 309: 293-300. 10.1016/S0003-2697(02)00311-1View ArticlePubMedGoogle Scholar
- Wardelmann E, Neidt I, Bierhoff E, Speidel N, Manegold C, Fischer HP, Pfeifer U, Pietsch T: c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol. 2002, 15: 125-136. 10.1038/modpathol.3880504View ArticlePubMedGoogle Scholar
- Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R, Bihl H, Leutner CC, Heinicke T, Hohenberger P: Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005, 6: 249-251. 10.1016/S1470-2045(05)70097-8View ArticlePubMedGoogle Scholar
- Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30: e36- 10.1093/nar/30.9.e36View ArticlePubMedPubMed CentralGoogle Scholar
- Sihto H, Franssila K, Tanner M, Vasama-Nolvi C, Sarlomo-Rikala M, Nupponen NN, Joensuu H, Isola J: Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours. Scand J Gastroenterol. 2006, 41: 805-811. 10.1080/00365520500483207View ArticlePubMedGoogle Scholar
- Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, Tamura K, Iwasaki H: Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab Invest. 2007, 87: 767-779. 10.1038/labinvest.3700591View ArticlePubMedGoogle Scholar
- Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R: Imatinib mesylate in chordoma. Cancer. 2004, 101: 2086-2097. 10.1002/cncr.20618View ArticlePubMedGoogle Scholar
- Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000, 25: 169-193. 10.1677/jme.0.0250169View ArticlePubMedGoogle Scholar
- Antonov J, Goldstein DR, Oberli A, Baltzer A, Pirotta M, Fleischmann A, Altermatt HJ, Jaggi R: Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest. 2005, 85: 1040-1050. 10.1038/labinvest.3700303View ArticlePubMedGoogle Scholar
- Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, Doucet D, Wickham E, Atkins D, Barker D, Chee M: Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol. 2004, 165: 1799-1807.View ArticlePubMedPubMed CentralGoogle Scholar
- Bustin SA: Why the need for qPCR publication guidelines?-The case for MIQE. Methods. 2010, 50: 217-226. 10.1016/j.ymeth.2009.12.006View ArticlePubMedGoogle Scholar
- Miettinen M, Sobin LH, Sarlomo-Rikala M: Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol. 2000, 13: 1134-1142. 10.1038/modpathol.3880210View ArticlePubMedGoogle Scholar
- Reichardt P: Optimal use of targeted agents for advanced gastrointestinal stromal tumours. Oncology. 2010, 78: 130-140. 10.1159/000312655View ArticlePubMedGoogle Scholar
- Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ: Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol. 1999, 23: 82-87. 10.1097/00000478-199901000-00009View ArticlePubMedGoogle Scholar
- Simon MP, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre JM, Terrier-Lacombe MJ, Mandahl N, Craver RD, Blin N: Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997, 15: 95-98. 10.1038/ng0197-95View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.